Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation

Neuroscience

Volumn 168, Issue 1, 2010, Pages 209-218

  Hackler, E A ^a,b   Byun, N E ^a,b   Jones, C K ^a,c,d   Williams, J M ^a,b   Baheza, R ^b   Sengupta, S ^b,e   Grier, M D ^d   Avison, M ^a,b,d   Conn, P J ^a,d   Gore, J C ^a,b,d,e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

Antipsychotic; BINA; BOLD; mGluR2; PhMRI; Schizophrenia

Indexed keywords

BIPHENYLINDANONE A; INDANONE DERIVATIVE; METABOTROPIC RECEPTOR 2; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG TARGETING; IN VIVO STUDY; LIMBIC SYSTEM; LOCOMOTION; MALE; NERVE STIMULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOMETRY; PUTAMEN; RAT; SCHIZOPHRENIA; SINGLE DRUG DOSE; THALAMUS; THALAMUS DORSOMEDIAL NUCLEUS;

ALLOSTERIC REGULATION; ANIMALS; BIPHENYL COMPOUNDS; BRAIN; DRUG EVALUATION, PRECLINICAL; INDANS; MAGNETIC RESONANCE IMAGING; MALE; MOTOR ACTIVITY; OXYGEN; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 77952889358     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.02.057     Document Type: Article

References (70)

1. Abel K.M., Allin M.P., Kucharska-Pietura K., Andrew C., Williams S., David A.S., Phillips M.L. Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum Brain Mapp 2003, 18:135-145.
2. Adams B.W., Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 2001, 50:750-757.
3. Andersen A.H., Gash D.M., Avison M.J. Principal component analysis of the dynamic response measured by fMRI: a generalized linear systems framework. Magn Reson Imaging 1999, 17:795-815.
4. Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev 1999, 29:83-120.
5. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 1994, 271:787-794.
6. Benneyworth M.A., Xiang Z., Smith R.L., Garcia E.E., Conn P.J., Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 2007, 72:477-484.
7. Cartmell J., Monn J.A., Schoepp D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999, 291:161-170.
8. Cartmell J., Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000, 75:889-907.
9. Cha J.H., Makowiec R.L., Penney J.B., Young A.B. L-[3H]glutamate labels the metabotropic excitatory amino acid receptor in rodent brain. Neurosci Lett 1990, 113:78-83.
10. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., Jenkins B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 1997, 38:389-398.
11. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205-237.
12. Daumann J., Heekeren K., Neukirch A., Thiel C.M., Moller-Hartmann W., Gouzoulis-Mayfrank E. Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl) 2008, 200:573-583.
13. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008, 65:154-164.
14. Detre J.A., Wang J. Technical aspects and utility of fMRI using BOLD and ASL. Clin Neurophysiol 2002, 113:621-634.
15. Dudley R.E., Nelson S.R., Samson F. Influence of chloralose on brain regional glucose utilization. Brain Res 1982, 233:173-180.
16. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 1999, 843:171-183.
17. Febo M., Ferris C.F., Segarra A.C. Estrogen influences cocaine-induced blood oxygen level-dependent signal changes in female rats. J Neurosci 2005, 25:1132-1136.
18. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2008, 326:209-217.
19. Galici R., Echemendia N.G., Rodriguez A.L., Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 2005, 315:1181-1187.
20. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., de Paulis T., Conn P.J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 2006, 318:173-185.
21. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93-97.
22. Gore J.C. Principles and practice of functional MRI of the human brain. J Clin Invest 2003, 112:4-9.
23. Gozzi A., Large C.H., Schwarz A., Bertani S., Crestan V., Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008, 33:1690-1703.
24. Gozzi A., Schwarz A., Crestan V., Bifone A. Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine. Magn Reson Imaging 2008, 26:999-1006.
25. Gozzi A., Schwarz A., Reese T., Bertani S., Crestan V., Bifone A. Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naive rat. Neuropsychopharmacology 2006, 31:1690-1703.
26. Gu G., Lorrain D.S., Wei H., Cole R.L., Zhang X., Daggett L.P., Schaffhauser H.J., Bristow L.J., Lechner S.M. Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition. Brain Res 2008, 1197:47-62.
27. Hackler E.A., Turner G.H., Gresch P.J., Sengupta S., Deutch A.Y., Avison M.J., Gore J.C., Sanders-Bush E. 5-Hydroxytryptamine 2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J Pharmacol Exp Ther 2007, 320:1023-1029.
28. Hajnal J.V., Myers R., Oatridge A., Schwieso J.E., Young I.R., Bydder G.M. Artifacts due to stimulus correlated motion in functional imaging of the brain. Magn Reson Med 1994, 31:283-291.
29. Henderson D.C. Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry 2007, 68(Suppl 12):18-26.
30. Hollmann M., Boulter J., Maron C., Heinemann S. Molecular biology of glutamate receptors. Potentiation of N-methyl-d-aspartate receptor splice variants by zinc. Ren Physiol Biochem 1994, 17:182-183.
31. Honey G.D., Corlett P.R., Absalom A.R., Lee M., Pomarol-Clotet E., Murray G.K., McKenna P.J., Bullmore E.T., Menon D.K., Fletcher P.C. Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo. J Neurosci 2008, 28:6295-6303.
32. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
33. Johnson M.P., Baez M., Jagdmann G.E., Britton T.C., Large T.H., Callagaro D.O., Tizzano J.P., Monn J.A., Schoepp D.D. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 2003, 46:3189-3192.
34. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., McKinzie D.L., Nisenbaum E.S., Tizzano J.P., Schoepp D.D. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 2005, 179:271-283.
35. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorguieva R., McDougall L., Hunsberger T., Belger A., Levine L., Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005, 179:303-309.
36. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., Abi-Saab W., Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999, 7:125-143.
37. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
38. Kurz M., Hummer M., Oberbauer H., Fleischhacker W.W. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995, 118:52-56.
39. Langsjo J.W., Kaisti K.K., Aalto S., Hinkka S., Aantaa R., Oikonen V., Sipila H., Kurki T., Silvanto M., Scheinin H. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003, 99:614-623.
40. Littlewood C.L., Jones N., O'Neill M.J., Mitchell S.N., Tricklebank M., Williams S.C. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology (Berl) 2006, 186:64-81.
41. Logothetis N.K., Pauls J., Augath M., Trinath T., Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature 2001, 412:150-157.
42. Matthysse S. Animal models in psychiatric research. Prog Brain Res 1986, 65:259-270.
43. Meltzer H.Y. What's atypical about atypical antipsychotic drugs?. Curr Opin Pharmacol 2004, 4:53-57.
44. Meyer-Lindenberg A., Weinberger D.R. Intermediate phenotypes and genetic mechanisms of psychiatrvic disorders. Nat Rev Neurosci 2006, 7:818-827.
45. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
46. Morrens M., Hulstijn W., Lewi P.J., De Hert M., Sabbe B.G. Stereotypy in schizophrenia. Schizophr Res 2006, 84:397-404.
47. Mouri A., Noda Y., Enomoto T., Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007, 51:173-184.
48. Nakanishi S. Glutamate receptors and brain function [in Japanese]. Seikagaku 1998, 70:1145-1158.
49. Nishijima K., Kashiwa A., Hashimoto A., Iwama H., Umino A., Nishikawa T. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse 1996, 22:304-312.
50. Northoff G., Richter A., Bermpohl F., Grimm S., Martin E., Marcar V.L., Wahl C., Hell D., Boeker H. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr Res 2005, 72:235-248.
51. Ogawa S., Lee T.M., Nayak A.S., Glynn P. Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magn Reson Med 1990, 14:68-78.
52. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 1993, 335:252-266.
53. Ori C., Dam M., Pizzolato G., Battistin L., Giron G. Effects of isoflurane anesthesia on local cerebral glucose utilization in the rat. Anesthesiology 1986, 65:152-156.
54. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13:1102-1107.
55. Paxinos G., Watson C. The rat brain in stereotactic coordinates 1998, Academic Press, San Diego, CA.
56. Richards C.D. The synaptic basis of general anaesthesia. Eur J Anaesthesiol 1995, 12:5-19.
57. Risterucci C., Jeanneau K., Schoppenthau S., Bielser T., Kunnecke B., von Kienlin M., Moreau J.L. Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl) 2005, 180:724-734.
58. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 1996, 7:3-23.
59. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38:1431-1476.
60. Schoepp D.D., Marek G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?. Curr Drug Targets CNS Neurol Disord 2002, 1:215-225.
61. Schwarz A.J., Zocchi A., Reese T., Gozzi A., Garzotti M., Varnier G., Curcuruto O., Sartori I., Girlanda E., Biscaro B., Crestan V., Bertani S., Heidbreder C., Bifone A. Concurrent pharmacological MRI and in situ microdialysis of cocaine reveal a complex relationship between the central hemodynamic response and local dopamine concentration. Neuroimage 2004, 23:296-304.
62. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr Res 2001, 49:1-52.
63. Spooren W.P., Gasparini F., van der Putten H., Koller M., Nakanishi S., Kuhn R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 2000, 397:R1-R2.
64. Sturgeon R.D., Fessler R.G., Meltzer H.Y. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 1979, 59:169-179.
65. Sugiyama H., Ito I., Watanabe M. Glutamate receptor subtypes may be classified into two major categories: a study on Xenopus oocytes injected with rat brain mRNA. Neuron 1989, 3:129-132.
66. Takahata R., Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 2003, 28:1117-1124.
67. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998, 12:21-36.
68. Thomas C.G., Harshman R.A., Menon R.S. Noise reduction in BOLD-based fMRI using component analysis. Neuroimage 2002, 17:1521-1537.
69. Williams J.M., Owens W.A., Turner G.H., Saunders C., Dipace C., Blakely R.D., France C.P., Gore J.C., Daws L.C., Avison M.J., Galli A. Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol 2007, 5:2369-2378.
70. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008, 196:431-440.